Established in 1983 and headquartered in Chandigarh, India, Ind-Swift Limited is a pharmaceutical enterprise specializing in the production and sale of a wide array of medicinal goods. Its product portfolio encompasses pharmaceutical formulations, finished dosage forms, active pharmaceutical ingredients (APIs), and natural herbal products. The company's offerings cater to numerous therapeutic areas, including ENT, dental care, infectious diseases, cardiovascular and diabetic conditions, and orthopedics, with prominent brands like Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte. Additionally, Ind-Swift provides medications for gynecology, pediatrics, dermatology, and general practice under names such as Anin, Suprox, Cozy, Distone, and Oliade. Their extensive range further extends to antibiotics, anti-cold remedies, nutraceuticals, anti-diarrheals, anti-malarials, antidepressants, and treatments for cardiology, diabetology, neurology, and oncology. Beyond its core product manufacturing, Ind-Swift also delivers contract research and manufacturing services. Its distribution network reaches government dispensaries, medical professionals, and hospitals through retailers, stockists, and various logistics channels. The company maintains a global footprint, exporting its products to approximately 50 countries.